1. Colchicine to Prevent Atrial Fibrillation Recurrence After Catheter Ablation: A Randomized, Placebo-Controlled Trial.
- Author
-
Benz AP, Amit G, Connolly SJ, Singh J, Acosta-Vélez JG, Conen D, Deif B, Divakaramenon S, McIntyre WF, Mtwesi V, Roberts JD, Wong JA, Zhao R, and Healey JS
- Subjects
- Female, Humans, Male, Middle Aged, Chest Pain prevention & control, Diarrhea etiology, Recurrence, Treatment Outcome, Atrial Fibrillation diagnosis, Atrial Fibrillation prevention & control, Catheter Ablation adverse effects, Catheter Ablation methods, Colchicine adverse effects, Colchicine therapeutic use
- Abstract
Background: Inflammation may promote atrial fibrillation (AF) recurrence after catheter ablation. This study aimed to evaluate a short-term anti-inflammatory treatment with colchicine following ablation of AF., Methods: Patients scheduled for ablation were randomized to receive colchicine 0.6 mg twice daily or placebo for 10 days. The first dose of the study drug was administered within 4 hours before ablation. Atrial arrhythmia recurrence was defined as AF, atrial flutter, or atrial tachycardia >30 s on two 14-day Holters performed immediately and at 3 months following ablation., Results: The modified intention-to-treat population included 199 patients (median age, 61 years; 22% female; 70% first procedure) who underwent radiofrequency (79%) or cryoballoon ablation (21%) of AF. Antiarrhythmic drugs were prescribed at discharge in 149 (75%) patients. Colchicine did not prevent atrial arrhythmia recurrence at 2 weeks (31% versus 32%; hazard ratio [HR], 0.98 [95% CI, 0.59-1.61]; P =0.92) or at 3 months following ablation (14% versus 15%; HR, 0.95 [95% CI, 0.45-2.02]; P =0.89). Postablation chest pain consistent with pericarditis was reduced with colchicine (4% versus 15%; HR, 0.26 [95% CI, 0.09-0.77]; P =0.02) and colchicine increased diarrhea (26% versus 7%; HR, 4.74 [95% CI, 1.95-11.53]; P <0.001). During a median follow-up of 1.3 years, colchicine did not reduce a composite of emergency department visit, cardiovascular hospitalization, cardioversion, or repeat ablation (29 versus 25 per 100 patient-years; HR, 1.18 [95% CI, 0.69-1.99]; P =0.55)., Conclusions: Colchicine administered for 10 days following catheter ablation did not reduce atrial arrhythmia recurrence or AF-associated clinical events, but did reduce postablation chest pain and increase diarrhea., Competing Interests: Disclosures Dr Benz reports lecture fees from Bristol Myers Squibb. Dr Amit reports serving on an advisory board for Johnson & Johnson. Dr Connolly reports institutional research grants and honoraria from Boehringer Ingelheim, Portola/Alexion Pharmaceuticals, Bristol Myers Squibb/Pfizer, Bayer, and Daiichi Sankyo. Dr Conen reports consultation fees from Roche Diagnostics and Trimedics and speaker fees from Servier and Bristol Myers Squibb/Pfizer. Dr McIntyre reports research support paid to his institution from AOP Pharma and honoraria from Trimed Therapeutics and Servier. Dr Roberts reports consulting fees from Bristol Myers Squibb and Ionis Pharmaceuticals. Dr Wong holds a McMaster University Department of Medicine Early Career Research Award and reports speaking fees from Biosense Webster. Dr Healey reports research grants and speaking fees from Medtronic and Boston Scientific and consulting fees from Boston Scientific. Other authors report no conflicts.
- Published
- 2024
- Full Text
- View/download PDF